Findings of Research Misconduct, 14020-14021 [2022-05217]
Download as PDF
14020
Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices
low sense of personal accomplishment
at work.1 Understanding the factors
impacting workforce well-being and
satisfaction, reducing burnout, and
applying evidence-based technical
assistance and other quality
improvement strategies around
workforce well-being is essential as the
health center program health care
workforce continues to respond to and
recover from the COVID–19 pandemic
and prepare for future health care
delivery challenges.
Administration of the Health Center
Workforce Survey will provide a
comprehensive baseline assessment of
health center workforce well-being and
identify opportunities to improve
workforce well-being and bolster
technical assistance and other strategies.
These efforts will further HRSA’s goal of
providing access to quality health care
and supporting a robust primary care
workforce.
Likely Respondents: Health center
staff in HRSA-funded health centers.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Health Center Workforce Survey .........................................
Health Center Leader Support Activities .............................
400,000
1,400
.50
2.00
200,000
2,800
401,400
........................
401,400
........................
202,800
1 West, C.P., Dyrbye, L.N., Satele, D.V, Sloan, J.A.,
& Shanafelt, T.D. (2012). Concurrent validity of
single-item measures of emotional exhaustion and
depersonalization in burnout assessment. J Gen
[FR Doc. 2022–05077 Filed 3–10–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Vaccine Injury Compensation
Program: Revised Amount of the
Average Cost of a Health Insurance
Policy
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
SUMMARY:
VerDate Sep<11>2014
17:10 Mar 10, 2022
Jkt 256001
PO 00000
Frm 00060
Total burden
hours
1
1
HRSA is publishing an
updated monetary amount of the
average cost of a health insurance policy
Maria G. Button,
Director, Executive Secretariat.
Average
burden per
response
(in hours)
Total
responses
400,000
1,400
as it relates to the National Vaccine
Injury Compensation Program (VICP).
FOR FURTHER INFORMATION CONTACT:
George Reed Grimes, Director, Division
of Injury Compensation Programs,
Health Systems Bureau, HRSA, HHS by
mail at 5600 Fishers Lane, 08N186B,
Rockville, Maryland 20857; call 1–800–
338–2382 or email
vaccinecompensation@hrsa.gov.
SUPPLEMENTARY INFORMATION: Section
100.2 of the VICP’s implementing
regulation (42 CFR part 100) states that
the revised amount of an average cost of
a health insurance policy, as determined
by the Secretary of HHS (the Secretary),
is effective upon its delivery by the
Secretary to the United States Court of
Federal Claims (the Court), and will be
published periodically in a notice in the
Federal Register. The Secretary
delegated this responsibility to the
HRSA Administrator. This figure is
calculated using the most recent
Medical Expenditure Panel SurveyInsurance Component (MEPS–IC) data
available as the baseline for the average
monthly cost of a health insurance
policy. This baseline is adjusted by the
annual percentage increase/decrease
obtained from the most recent annual
Kaiser Family Foundation (KFF)
Employer Health Benefits Survey or
other authoritative sources that may be
more accurate or appropriate.
In 2021, MEPS–IC, available at
www.meps.ahrq.gov, published the
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
lotter on DSK11XQN23PROD with NOTICES1
Number of
responses per
respondent
Fmt 4703
Sfmt 4703
annual 2020 average total single
premium per enrolled employee at
private-sector establishments that
provide health insurance. The figure
published was $7,149. This figure is
divided by 12 to determine the cost per
month of $595.75. The $595.75 figure is
increased or decreased by the
percentage change reported by the most
recent KFF Employer Health Benefits
Survey, available at www.kff.org. The
increase from 2020 to 2021 was 4.0
percent. By adding this percentage
increase, the calculated average monthly
cost of a health insurance policy for a
12-month period is $619.58.
Therefore, the revised average cost of
a health insurance policy under the
VICP is $619.58 per month. In
accordance with § 100.2, the revised
amount was effective upon its delivery
to the Court.
Carole Johnson,
Administrator.
[FR Doc. 2022–05220 Filed 3–10–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY:
Office of the Secretary, HHS.
Intern Med, 27 (11 PG–1445–52), 1445–1452.
https://doi.org/10.1007/s11606-012-2015-7.
E:\FR\FM\11MRN1.SGM
11MRN1
Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices
ACTION:
Notice.
Findings of research
misconduct have been made against
Terry Magnuson, Ph.D. (Respondent),
Kay M. & Van L. Weatherspoon Eminent
Distinguished Professor, Department of
Genetics, School of Medicine (SOM),
University of North Carolina at Chapel
Hill (UNC). Respondent engaged in
research misconduct in research
included in one (1) grant application for
U.S. Public Health Service (PHS) funds,
specifically National Cancer Institute
(NCI), National Institutes of Health
(NIH), grant application R01 CA267946–
01A1. The administrative actions,
including supervision from February 25,
2022–January 5, 2024, are detailed
below.
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Terry Magnuson, Ph.D., University of
North Carolina at Chapel Hill: Based on
the report of an assessment conducted
by UNC, Respondent’s admission, and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Terry Magnuson, Kay M. & Van L.
Weatherspoon Eminent Distinguished
Professor, Department of Genetics,
SOM, UNC, engaged in research
misconduct in research included in one
(1) grant application for PHS funds,
specifically NCI, NIH, grant application
R01 CA267946–01A1.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, or recklessly plagiarizing
text from the following three (3) online
articles and one (1) published paper:
• Comprehensive Guide to
Understanding and Using CUT&Tag
Assay. November 4, 2020. https://
www.activemotif.com/blog-cut-tag
(hereafter referred as ‘‘Blog cut&tag
2020’’).
• Complete Guide to Understanding
and Using ATAC-Seq. February 9, 2021.
https://www.activemotif.com/blog-atacseq (hereafter referred as ‘‘Blog ATACSeq 2021’’).
• Illumina CATCH–IT. https://
www.illumina.com/science/sequencingmethod-explorer/kits-and-arrays/catchit.html (hereafter referred as ‘‘Illumina
Catch-it’’).
• Modeling Physiological Events in
2D vs. 3D Cell Culture. Physiology
(Bethesda) 2017 Jul;32(4):266–277; doi:
10.1152/physiol.00036.2016 (hereafter
VerDate Sep<11>2014
17:10 Mar 10, 2022
Jkt 256001
referred as ‘‘Physiology (Bethesda)
2017’’).
Plagiarized text was included in:
• Grant application R01 CA267946–
01A1, ‘‘Genome-wide dynamics of
chromatin modifiers,’’ submitted to
NCI, NIH, on March 1, 2021 (hereafter
referred as ‘‘R01 CA267946–01A1’’)
Specifically, ORI found that
Respondent knowingly, intentionally, or
recklessly plagiarized from:
• The introduction (p. 266) and
techniques (p. 267) sections of
Physiology (Bethesda) 2017 to
compose subsection ‘‘ii. Identifying
changes to SWI/SNF composition
driven by cell state changes’’ of
Specific Aim 1 of R01 CA267946–
01A1
• the introduction and sections ‘‘What
is CUT&Tag’’ and ‘‘Before CUT&Tag,
There Was CUT&RUN’’ of Blog
cut&tag 2020 to compose the ‘‘CHIPseq protocols’’ description in R01
CA267946–01A1
• the ‘‘What is ATAC-Seq?’’ section of
Blog ATAC-Seq 2021 to compose the
‘‘ATAC-seq protocols’’ description in
R01 CA267946–01A1
• the web page ‘‘Illumina Catch-it’’
describing the CATCH–IT technology
to compose the ‘‘Pitfalls &
Alternatives’’ section of Specific Aim
1 in R01 CA267946–01A1
Dr. Magnuson entered into a
Voluntary Settlement Agreement
(Agreement) and voluntarily agreed to
the following:
(1) Respondent will have his research
supervised from February 25, 2022–
January 5, 2024 (the ‘‘Supervision
Period’’). Prior to the submission of an
application for PHS support for a
research project on which Respondent’s
participation is proposed and prior to
Respondent’s participation in any
capacity in PHS-supported research,
Respondent will submit a plan for
supervision of Respondent’s duties to
ORI for approval. The supervision plan
must be designed to ensure the integrity
of Respondent’s research. Respondent
will not participate in any PHSsupported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. The respondent will submit his
grant applications seeking PHS support
to the Vice Dean, UNC SOM, thirty (30)
days prior to the grant application
submission deadline. The SOM Office of
Research (OR) will review Respondent’s
grant applications to check for
plagiarism and ensure compliance with
acceptable scientific practice for citation
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
14021
of prior work. SOM OR will not recruit
Respondent’s supervisor or
collaborators to review his grant
applications. SOM OR will submit a
report to ORI at six (6) month intervals
setting forth the committee meeting
dates and Respondent’s compliance
with appropriate research standards and
confirming the integrity of Respondent’s
research.
ii. SOM OR will conduct an advance
review of any report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved. The review will include a
discussion with Respondent of the
primary data represented in those
documents and will include a
certification to ORI that the data
presented and the text in the report,
manuscript, or abstract is supported by
the research record and not plagiarized.
(3) During the Supervision Period,
Respondent will ensure that any
institution employing him submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported and not plagiarized
in the application, report, manuscript,
or abstract.
(4) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that his
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that he has not
participated in any capacity in PHSsupported research.
Dated: March 8, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–05217 Filed 3–10–22; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Impact of Health Misinformation in the
Digital Information Environment in the
United States Throughout the COVID–
19 Pandemic Request for Information
(RFI); Correction
Office of the Surgeon General,
Department of Health and Human
Services.
ACTION: Notice; correction.
AGENCY:
E:\FR\FM\11MRN1.SGM
11MRN1
Agencies
[Federal Register Volume 87, Number 48 (Friday, March 11, 2022)]
[Notices]
[Pages 14020-14021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-05217]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
[[Page 14021]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Terry
Magnuson, Ph.D. (Respondent), Kay M. & Van L. Weatherspoon Eminent
Distinguished Professor, Department of Genetics, School of Medicine
(SOM), University of North Carolina at Chapel Hill (UNC). Respondent
engaged in research misconduct in research included in one (1) grant
application for U.S. Public Health Service (PHS) funds, specifically
National Cancer Institute (NCI), National Institutes of Health (NIH),
grant application R01 CA267946-01A1. The administrative actions,
including supervision from February 25, 2022-January 5, 2024, are
detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Terry Magnuson, Ph.D., University of North Carolina at Chapel Hill:
Based on the report of an assessment conducted by UNC, Respondent's
admission, and additional analysis conducted by ORI in its oversight
review, ORI found that Dr. Terry Magnuson, Kay M. & Van L. Weatherspoon
Eminent Distinguished Professor, Department of Genetics, SOM, UNC,
engaged in research misconduct in research included in one (1) grant
application for PHS funds, specifically NCI, NIH, grant application R01
CA267946-01A1.
ORI found that Respondent engaged in research misconduct by
intentionally, knowingly, or recklessly plagiarizing text from the
following three (3) online articles and one (1) published paper:
Comprehensive Guide to Understanding and Using CUT&Tag
Assay. November 4, 2020. https://www.activemotif.com/blog-cut-tag
(hereafter referred as ``Blog cut&tag 2020'').
Complete Guide to Understanding and Using ATAC-Seq.
February 9, 2021. https://www.activemotif.com/blog-atac-seq (hereafter
referred as ``Blog ATAC-Seq 2021'').
Illumina CATCH-IT. https://www.illumina.com/science/sequencing-method-explorer/kits-and-arrays/catch-it.html (hereafter
referred as ``Illumina Catch-it'').
Modeling Physiological Events in 2D vs. 3D Cell Culture.
Physiology (Bethesda) 2017 Jul;32(4):266-277; doi: 10.1152/
physiol.00036.2016 (hereafter referred as ``Physiology (Bethesda)
2017'').
Plagiarized text was included in:
Grant application R01 CA267946-01A1, ``Genome-wide dynamics of
chromatin modifiers,'' submitted to NCI, NIH, on March 1, 2021
(hereafter referred as ``R01 CA267946-01A1'')
Specifically, ORI found that Respondent knowingly, intentionally,
or recklessly plagiarized from:
The introduction (p. 266) and techniques (p. 267) sections of
Physiology (Bethesda) 2017 to compose subsection ``ii. Identifying
changes to SWI/SNF composition driven by cell state changes'' of
Specific Aim 1 of R01 CA267946-01A1
the introduction and sections ``What is CUT&Tag'' and ``Before
CUT&Tag, There Was CUT&RUN'' of Blog cut&tag 2020 to compose the
``CHIP-seq protocols'' description in R01 CA267946-01A1
the ``What is ATAC-Seq?'' section of Blog ATAC-Seq 2021 to
compose the ``ATAC-seq protocols'' description in R01 CA267946-01A1
the web page ``Illumina Catch-it'' describing the CATCH-IT
technology to compose the ``Pitfalls & Alternatives'' section of
Specific Aim 1 in R01 CA267946-01A1
Dr. Magnuson entered into a Voluntary Settlement Agreement
(Agreement) and voluntarily agreed to the following:
(1) Respondent will have his research supervised from February 25,
2022-January 5, 2024 (the ``Supervision Period''). Prior to the
submission of an application for PHS support for a research project on
which Respondent's participation is proposed and prior to Respondent's
participation in any capacity in PHS-supported research, Respondent
will submit a plan for supervision of Respondent's duties to ORI for
approval. The supervision plan must be designed to ensure the integrity
of Respondent's research. Respondent will not participate in any PHS-
supported research until such a supervision plan is approved by ORI.
Respondent will comply with the agreed-upon supervision plan.
(2) The requirements for Respondent's supervision plan are as
follows:
i. The respondent will submit his grant applications seeking PHS
support to the Vice Dean, UNC SOM, thirty (30) days prior to the grant
application submission deadline. The SOM Office of Research (OR) will
review Respondent's grant applications to check for plagiarism and
ensure compliance with acceptable scientific practice for citation of
prior work. SOM OR will not recruit Respondent's supervisor or
collaborators to review his grant applications. SOM OR will submit a
report to ORI at six (6) month intervals setting forth the committee
meeting dates and Respondent's compliance with appropriate research
standards and confirming the integrity of Respondent's research.
ii. SOM OR will conduct an advance review of any report,
manuscript, or abstract involving PHS-supported research in which
Respondent is involved. The review will include a discussion with
Respondent of the primary data represented in those documents and will
include a certification to ORI that the data presented and the text in
the report, manuscript, or abstract is supported by the research record
and not plagiarized.
(3) During the Supervision Period, Respondent will ensure that any
institution employing him submits, in conjunction with each application
for PHS funds, or report, manuscript, or abstract involving PHS-
supported research in which Respondent is involved, a certification to
ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported and not plagiarized
in the application, report, manuscript, or abstract.
(4) If no supervision plan is provided to ORI, Respondent will
provide certification to ORI at the conclusion of the Supervision
Period that his participation was not proposed on a research project
for which an application for PHS support was submitted and that he has
not participated in any capacity in PHS-supported research.
Dated: March 8, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2022-05217 Filed 3-10-22; 8:45 am]
BILLING CODE 4150-31-P